4 days ago · Novo Nordisk plans further clinical development of amycretin for obesity and overweight treatment. ... Investigators reported that treatment with amycretin showed an …

Jan 28, 2025 · Novo Nordisk has reported weight loss effects of up to 22% in patients who received a weekly subcutaneous dose of its next-generation weight loss drug, amycretin, over …

Jan 27, 2025 · A next-generation weight-loss drug. Amycretin is considered as Novo Nordisk’s most competitive treatment in its weight-loss pipeline for obesity and type-2 diabetes, as the …

Jan 27, 2025 · Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight individuals. ... Subjects receiving the therapy …

Jan 24, 2025 · One of Novo Nordisk's next-generation obesity shots to follow up on the success of Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial …

Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t …

Jan 17, 2025 · Those who received once-weekly semaglutide 7.2 mg lost 20.7% of their body weight on average after 72 weeks versus 17.5% weight loss with semaglutide 2.4 mg and just …

Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection …

Sep 11, 2024 · Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to 13.1% weight loss after 12 weeks—and …

Sep 23, 2024 · An experimental new pill from Novo Nordisk, called amycretin, could cause substantial weight loss in people with obesity. The once-daily oral medication is in the same …